PCVX
PCVX
Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
0
$0
Insider Sales
40
$23.06M
Total Volume
$23.06M
40 transactions
Net Activity
$23.06M
Net selling
Sentiment Rating
Heavy DistributionCEO Conviction Index
Liquidating / Profit Taking
Key Drivers
- •Heavy distribution: sales represent 100% of total transaction value.
- •CEO selling activity detected. Often driven by option expiration or diversification plans.
- •Significant liquidation: total sale value exceeds $10M.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
Wassil Jim
EVP, Chief Scientific Ofc, COO
$5.94M total
Pickering Grant
CEO
$5.24M total
Guggenhime Andrew
Pres, CFO
$4.40M total
Cowan Elvia
SVP, Finance, CAO
$2.71M total
Dhaliwal Harpreet S.
Chief Technical Ops Officer
$2.54M total
Quick Actions
PCVX has an insider buy conviction of 0%, compared to the Unknown sector buy average of 6%. PCVX ranks #312 in insider activity out of 569 tracked companies in its industry.
Over the last 90 days, corporate insiders at PCVX (PCVX) engaged in a total of 40 transactions reported via SEC Form 4 filings. Among these, 0 were open-market purchases and 40 were sales. The total volume of insider trading reached $23.06M.
The net insider activity for PCVX shows a net selling bias of $23.06M. This activity represents a 0% buy ratio, suggesting that insiders are currently bearish on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Sale by Cowan Elvia (SVP, Finance, CAO), who traded 19.0K shares valued at $1.65M on Oct 5, 2026.
Wall Street Analysts See an 87.35% Upside in Vaxcyte (PCVX): Can the Stock Really Move This High?
Vaxcyte Stock Hits New 52-Week High - Here’s Why
Small Biotech Squares Up To Pfizer, Merck In $7 Billion Market
PCVX Stock Hits Fresh 52-Week High On Late-Stage Win In Adult Pneumonia Vaccine Race: Jefferies Says It Hit ‘Blue-Sky’ Case
PCVX Stock Builds Tension Ahead Of Key OPUS-1 Data
PCVX Stock Heats Up As OPUS-1 Catalyst Looms Large
FAQs About PCVX Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for PCVX.